Multivariate model evaluating transplant outcomes classified according to allele and antigen mismatches at HLA-C
| . | 8/8 Match . | 7/8 C*03:03/C*03:04 mismatch . | 7/8 HLA-A, -B, or -DRB1 mismatch . | 7/8 C-antigen mismatch . | 7/8 Other C-allele mismatch . | Overall comparison . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 4779 . | n = 134 . | n = 959 . | n = 700 . | n = 61 . | . | |||||||||
| HR . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | P . | |
| OS* | 1.00 | 0.98 | (0.78-1.23) | .85 | 1.30 | (1.19-1.43) | <.0001 | 1.37 | (1.24-1.51) | <.0001 | 1.43 | (1.06-1.92) | .02 | <.0001 |
| DFS† | 1.00 | 1.00 | (0.80-1.25) | .99 | 1.27 | (1.17-1.38) | <.0001 | 1.33 | (1.20-1.46) | <.0001 | 1.34 | (0.99-1.80) | .06 | <.0001 |
| TRM‡ | 1.00 | 1.05 | (0.79-1.40) | .73 | 1.54 | (1.39-1.71) | <.0001 | 1.54 | (1.39-1.74) | <.0001 | 1.60 | (1.10-2.33) | .02 | <.0001 |
| 3-4 aGVHD§ | 1.00 | 0.96 | (0.67-1.38) | .83 | 1.77 | (1.56-2.01) | <.0001 | 1.49 | (1.28-1.73) | <.0001 | 1.72 | (1.11-2.69) | .02 | <.0001 |
| 2-4 aGVHD|| | 1.00 | 0.97 | (0.76-1.25) | .83 | 1.30 | (1.18-1.43) | <.0001 | 1.15 | (1.02-1.28) | .02 | 1.56 | (1.11-2.19) | .01 | <.0001 |
| Absence of neutrophil engraftment at day 28¶ | 1.00 | 0.63 | (0.29-1.33) | .23 | 1.19 | (0.97-1.47) | .10 | 1.28 | (1.02-1.61) | .03 | 1.19 | (0.51-2.78) | .68 | .09 |
| Relapse# | 1.00 | 0.94 | (0.66-1.32) | .71 | 0.93 | (0.81-1.08) | .35 | 1.03 | (0.88-1.20) | .76 | 1.00 | (0.62-1.64) | .99 | .88 |
| cGvHD** | 1.00 | 0.92 | (0.72-1.19) | .53 | 1.04 | (0.94-1.16) | .44 | 1.02 | (0.90-1.16) | .76 | 1.08 | (0.75-1.57) | .91 | .67 |
| . | 8/8 Match . | 7/8 C*03:03/C*03:04 mismatch . | 7/8 HLA-A, -B, or -DRB1 mismatch . | 7/8 C-antigen mismatch . | 7/8 Other C-allele mismatch . | Overall comparison . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 4779 . | n = 134 . | n = 959 . | n = 700 . | n = 61 . | . | |||||||||
| HR . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | P . | |
| OS* | 1.00 | 0.98 | (0.78-1.23) | .85 | 1.30 | (1.19-1.43) | <.0001 | 1.37 | (1.24-1.51) | <.0001 | 1.43 | (1.06-1.92) | .02 | <.0001 |
| DFS† | 1.00 | 1.00 | (0.80-1.25) | .99 | 1.27 | (1.17-1.38) | <.0001 | 1.33 | (1.20-1.46) | <.0001 | 1.34 | (0.99-1.80) | .06 | <.0001 |
| TRM‡ | 1.00 | 1.05 | (0.79-1.40) | .73 | 1.54 | (1.39-1.71) | <.0001 | 1.54 | (1.39-1.74) | <.0001 | 1.60 | (1.10-2.33) | .02 | <.0001 |
| 3-4 aGVHD§ | 1.00 | 0.96 | (0.67-1.38) | .83 | 1.77 | (1.56-2.01) | <.0001 | 1.49 | (1.28-1.73) | <.0001 | 1.72 | (1.11-2.69) | .02 | <.0001 |
| 2-4 aGVHD|| | 1.00 | 0.97 | (0.76-1.25) | .83 | 1.30 | (1.18-1.43) | <.0001 | 1.15 | (1.02-1.28) | .02 | 1.56 | (1.11-2.19) | .01 | <.0001 |
| Absence of neutrophil engraftment at day 28¶ | 1.00 | 0.63 | (0.29-1.33) | .23 | 1.19 | (0.97-1.47) | .10 | 1.28 | (1.02-1.61) | .03 | 1.19 | (0.51-2.78) | .68 | .09 |
| Relapse# | 1.00 | 0.94 | (0.66-1.32) | .71 | 0.93 | (0.81-1.08) | .35 | 1.03 | (0.88-1.20) | .76 | 1.00 | (0.62-1.64) | .99 | .88 |
| cGvHD** | 1.00 | 0.92 | (0.72-1.19) | .53 | 1.04 | (0.94-1.16) | .44 | 1.02 | (0.90-1.16) | .76 | 1.08 | (0.75-1.57) | .91 | .67 |
In bold are shown statistically significant comparisons made with the reference 8/8 matched group.
Adjusted for cytomegalovirus match, disease type, disease stage, GVHD prophylaxis, patient age, sex match, graft type, Karnofsky score, time from diagnosis to transplantation, and year of transplantation.
Adjusted for cytomegalovirus match, disease type, GVHD prophylaxis, patient age, in vivo T-cell depletion, disease stage, graft type, Karnofsky score, and year of transplantation.
Adjusted for cytomegalovirus match, conditioning regimen, disease type, disease stage, GVHD prophylaxis, patient age, donor age, sex match, graft type, Karnofsky score, and year of transplantation.
Adjusted for conditioning regimen, disease stage, Karnofsky score, patient age, sex match, year of transplantation, disease type, GVHD prophylaxis, and in vivo T-cell depletion.
Adjusted for disease type, graft type, sex match, year of transplantation, GVHD prophylaxis, in vivo T-cell depletion, conditioning regimen, and patient age.
Adjusted for disease stage, donor age, conditioning regimen, graft type, in vivo T-cell depletion, GVHD prophylaxis, and Karnofsky score.
Adjusted for time from diagnosis to transplantation, Karnofsky score, patient age, sex match, disease type, disease stage, conditioning regimen, and year of transplantation.
Adjusted for donor age, graft type, in vivo T-cell depletion, patient age, sex match, year of transplantation, disease type, and GVHD prophylaxis.